<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03846479</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 18-1684</org_study_id>
    <nct_id>NCT03846479</nct_id>
  </id_info>
  <brief_title>Itacitinib for Low Risk GVHD</brief_title>
  <official_title>Itacitinib Monotherapy for Low Risk Graft-vs-Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John Levine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Graft-versus-host disease (GVHD) is treated with high doses of systemic steroids which can
      lead to serious complications. A new blood test can identify patients whose GVHD is most
      likely to respond to well to treatment (low risk GVHD). This study will test whether patients
      with low risk GVHD can be successfully treated without steroids. Patients who participate
      with this study will be treated with itacitinib instead of steroids. Itacitinib is an
      experimental drug with an excellent safety record and appears to have activity as a GVHD
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label, single arm, non-inferiority study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Minnesota standard risk clinical criteria</measure>
    <time_frame>Day 28</time_frame>
    <description>The Minnesota standard risk clinical criteria is defined as CR= complete remission, PR = partial remission, and TRM - treatment related mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ann Arbor Score 1 (AA1)</measure>
    <time_frame>Day 28</time_frame>
    <description>Ann Arbor Score - a scoring system that uses an algorithm of three biomarkers (TNFR1, ST2 and REG3a). A low Ann Arbor Score is Ann Arbor 1 (AA1) =&lt;10%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Day 28</time_frame>
    <description>Number of adverse events at Day 28 to assess safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious infectious complications</measure>
    <time_frame>Day 90</time_frame>
    <description>The incidence of serious infectious complications in patients with GVHD treated with itacitinib. Serious infectious complications is defined as any viral and bacterial infections requiring treatment and proven fungal infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Day 56</time_frame>
    <description>Number of overall response rate (ORR), defined as complete and partial responses.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Low Risk Acute Graft-versus-host Disease</condition>
  <condition>Graft-versus-host-disease</condition>
  <condition>GVHD</condition>
  <arm_group>
    <arm_group_label>Itacitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Itacitinib 200 mg administered orally daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itacitinib</intervention_name>
    <description>for up to 56 days</description>
    <arm_group_label>Itacitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed GVHD that meets criteria for Minnesota standard risk

          -  Ann Arbor 1 GVHD by biomarkers

          -  GVHD not previously treated systemically (topical therapies and non-absorbed steroids
             are allowed)

          -  Any donor type, HLA-match, conditioning regimen is acceptable

          -  Age 12 - 75 years (children &lt;18 years must also weigh 50 kg or more)

          -  Patients must be engrafted post-transplant (ANC &gt;500/Î¼L and platelet count &gt;20,000).
             Use of growth factor supplementation to maintain neutrophil count is allowed.

          -  Direct bilirubin must be &lt;2 mg/dL unless the elevation is known to be due to Gilbert
             syndrome within 3 days prior to enrollment.

          -  ALT/SGPT and AST/SGOT must be &lt;5x the upper limit of the normal range within 3 days
             prior to enrollment.

          -  Signed and dated written informed consent obtained from patient or legal
             representative.

        Exclusion Criteria:

          -  Patients currently being treated with any JAK inhibitor including ruxolitinib

          -  Relapsed, progressing, or persistent malignancy requiring withdrawal of systemic
             immune suppression

          -  Patients with uncontrolled infection (i.e., progressive symptoms related to infection
             despite treatment or persistently positive microbiological cultures despite treatment
             or any other evidence of severe sepsis)

          -  Severe organ dysfunction including requirement for dialysis, mechanical ventilation or
             oxygen supplementation exceeding 40% FiO2 within 7 days of enrollment.

          -  Creatinine clearance or estimated glomerular filtration rate &lt;30 ml/min as calculated
             by institutional practice (e.g., Cockcroft-Gault equation, CKD-EPI equation, etc)

          -  A clinical presentation resembling de novo chronic GVHD or overlap syndrome developing
             before or present at the time of enrollment

          -  Patients receiving corticosteroids &gt;10 mg/day prednisone (or other steroid equivalent)
             for any indication within 7 days before the onset of acute GVHD except for adrenal
             insufficiency or premedication for transfusions/IV meds

          -  Patients who are pregnant

          -  Patients receiving investigational agents within 30 days of enrollment. However, the
             Principal Investigator (PI) may approve prior use of an investigational agent if the
             agent is not expected to interfere with the safety or the efficacy of itacitinib

          -  History of allergic reaction to itacitinib or any JAK inhibitor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Levine, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel Young</last_name>
    <phone>212-659-5605</phone>
    <email>rachel.young@mssm.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryotara Nakamura, MD</last_name>
      <phone>626-256-4673</phone>
      <email>rnakamura@coh.org</email>
    </contact>
    <investigator>
      <last_name>Ryotara Nakamura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Pulsipher, MD</last_name>
      <phone>323-361-2546</phone>
      <email>mpulsipher@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Pulsipher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edmund Waller, MD</last_name>
      <phone>404-727-4995</phone>
      <email>ewaller@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Edmund Waller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muna Qayed, MD</last_name>
      <phone>404-785-6177</phone>
      <email>muna.qayed@choa.org</email>
    </contact>
    <investigator>
      <last_name>Muna Qayed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sunil Abhyankar, MD</last_name>
      <phone>913-588-6030</phone>
      <email>sabhyankar@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Sunil Abhyankar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi-Bin Chen, MD</last_name>
      <phone>617-724-1124</phone>
      <email>ychen6@partners.org</email>
    </contact>
    <investigator>
      <last_name>Yi-Bin Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Hogan, MD</last_name>
      <phone>507-319-6580</phone>
      <email>hogan.william@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>William Hogan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Young</last_name>
      <phone>212-659-5605</phone>
      <email>rachel.young@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>John Levine, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Choe, MD</last_name>
      <phone>614-293-3271</phone>
      <email>hannah.choe@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Hannah Choe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephen Grupp, MD</last_name>
      <phone>215-590-5475</phone>
      <email>grupp@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Grupp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Porter, MD</last_name>
      <phone>215-662-2862</phone>
      <email>david.porter@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>David Porter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Kitko, MD</last_name>
      <phone>615-936-2088</phone>
      <email>carrie.l.kitko@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Carrie Kitko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amin Alousi, MD</last_name>
      <phone>713-745-8613</phone>
      <email>aalousi@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Amin Alousi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chelsea E Cossairt</last_name>
      <email>ccossair@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Marco Mielcarek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>February 17, 2019</study_first_submitted>
  <study_first_submitted_qc>February 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>December 20, 2019</last_update_submitted>
  <last_update_submitted_qc>December 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>John Levine</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Graft-versus-host disease</keyword>
  <keyword>Itacitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

